Agf Management LTD Neurocrine Biosciences Inc Transaction History

Agf Management LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$130.4 - $143.74 $1.07 Million - $1.18 Million	-8,209 Reduced 33.04%	16,637 $2.29 Million
Q4 2023 Feb 07, 2024	SELL	$106.07 - $132.76 $389,170 - $487,096	-3,669 Reduced 12.87%	24,846 $3.27 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $854,077 - $1.06 Million	-9,084 Reduced 24.16%	28,515 $3.21 Million
Q2 2023 Aug 09, 2023	BUY	$89.53 - $104.87 $286,227 - $335,269	3,197 Added 9.29%	37,599 $3.55 Million
Q1 2023 May 03, 2023	BUY	$94.11 - $123.02 $674,392 - $881,561	7,166 Added 26.31%	34,402 $3.48 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $2.91 Million - $3.46 Million	27,236 New	27,236 $0

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Agf Management LTD, based on Form 13F filings with the SEC.

Stay updated on Agf Management LTD with notifications on news.